Acetazolamide Pediatric Dose — Diuretics
Acetazolamide is a carbonic anhydrase inhibitor diuretic that reduces bicarbonate reabsorption in the proximal tubule, promoting urinary excretion of sodium, potassium, and water. In pediatric practice, it is utilized for its diuretic properties as well as adjunctive management of metabolic alkalosis, elevated intracranial pressure, and certain seizure disorders. Its dual IV and oral availability makes it a flexible option in both inpatient and outpatient settings.
Pediatric Dosing
- 5 mg/kg per dose administered IV or PO
- Frequency: every 6–12 hours
- Duration: for 24 hours
The dosing interval (every 6 vs. every 12 hours) should be guided by the clinical indication, patient response, and institutional protocol. Consult institutional protocol for maximum single-dose limits not specified in this source.
Worked example: For a 20 kg child: 20 × 5 mg/kg = 100 mg per dose, given every 6–12 hours for 24 hours (2–4 doses total).
Indications and Clinical Context
Acetazolamide is indicated as a diuretic agent in pediatric patients when carbonic anhydrase inhibition is the desired mechanism. Common clinical scenarios include management of metabolic alkalosis (particularly post-diuretic or post-cardiac surgery alkalosis), adjunctive treatment of elevated intracranial pressure, and certain glaucoma indications. It is classified within the diuretic category and is typically used as a short-course or adjunctive agent rather than a primary long-term diuretic.
The 24-hour limited course reflected in this dosing description is consistent with its use in acute, targeted clinical settings. Clinicians should reassess the need for continued therapy beyond 24 hours based on patient response and underlying condition.
Administration and Monitoring
Acetazolamide may be administered intravenously (direct IV injection or short infusion) or orally. IV formulations should be reconstituted per institutional guidelines and given slowly. Oral tablets may be crushed and suspended for younger patients who cannot swallow whole tablets, though palatability may be limited.
- Electrolytes: Monitor serum sodium, potassium, bicarbonate, and chloride closely, as acetazolamide promotes potassium and bicarbonate wasting.
- Acid-base status: Metabolic acidosis is a known dose-dependent adverse effect; monitor blood gas or serum bicarbonate.
- Renal function: Use with caution in renal impairment; consult institutional protocol for dose adjustment.
- Contraindications: Avoid in patients with sulfonamide hypersensitivity, significant hepatic disease, hyponatremia, or hypokalemia refractory to correction.
- Duration: Source specifies use for 24 hours only; extended use requires reassessment and clinical justification.
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.